Why Did Trevi Therapeutics Plunge 17.42% Despite Positive Analyst Ratings?

On April 16, 2025, Trevi Therapeutics experienced a significant drop of 17.42% in pre-market trading, indicating a notable shift in investor sentiment towards the company.

Analysts have given Trevi Therapeutics a consensus rating of Buy, with an average rating score of 3.30. This rating is based on seven buy ratings, with no hold or sell ratings, suggesting a generally positive outlook among analysts.

Despite the recent upgrade and bullish sentiment, analysts have forecasted a negative earnings per share of -0.49 for the current year. This discrepancy between the positive ratings and the negative earnings forecast may have contributed to the recent stock price decline.

In the most recent quarter, Trevi Therapeutics reported earnings per share (EPS) of -$0.11, which was slightly better than analysts' consensus estimates of -$0.12. This slight beat may not have been enough to offset the negative earnings forecast for the year.